Lantheus Medical Imaging of North Billerica, MA, said that a new study published in the January/February 2009 issue of the Journal of Nuclear Cardiology finds that the use of SPECT myocardial perfusion imaging (MPI) with its Cardiolite radiopharmaceutical is useful for diagnosing coronary artery disease (CAD) in patients with new-onset heart failure.
The study assessed 201 patients at 14 sites in the U.S. and the U.K. All patients received a stress and rest SPECT MPI test using Cardiolite, and found that SPECT MPI had 96% sensitivity, 56% specificity, and a 96% negative predictive value for diagnosing extensive CAD.
The diagnostic values of SPECT MPI for more limited CAD were 82% sensitivity, 57% specificity, and 75% negative predictive value. These definitions were used to differentiate heart failure patients with extensive, etiologically relevant CAD from those with more limited, coexisting CAD, Lantheus reported.
Related Reading
Lantheus touts positive Definity results, December 16, 2008
Lantheus scores Premier contract, October 24, 2008
Lantheus to license Bracco's CardioGen PET tracer, September 24, 2008
Definity echo contrast agent lands on FDA drug safety list, September 8, 2008
IBA, Lantheus ink radiopharma deal, July 31, 2008
Copyright © 2009 AuntMinnie.com
